Oculis

Biotechnology, Health Care, Pharmaceutical
Founded in 2003-01-01
Reykjavík, Gullbringusysla, Iceland
For Profit

About Oculis

The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops.

Company Metrics

  • Employees: 11-50
  • Monthly Visits: 762
  • Tech Stack: 21 active products

Financial Information

  • Estimated Revenue:
  • Total Funding: 94355910 USD
  • Last Funding: 57000000 USD (Series C)
  • Funding Status: Late Stage Venture

Technology Stack

Oculis actively uses 21 products in their tech stack.

Market Presence

Industries: Biotechnology, Health Care, Pharmaceutical

Headquarters: Reykjavík, Gullbringusysla, Iceland